Brief: Regulus Therapeutics Announces Completion Of Enrollment In Third Cohort Of Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429
02/01/2024 21:09
Jan 2 (Reuters) - Regulus Therapeutics Inc RGLS.O :
* REGULUS THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN
THIRD
COHORT OF PHASE 1B MULTIPLE-ASCENDING DOSE (MAD) CLINICAL TRIAL
OF RGLS8429 FOR THE TREATMENT OF PATIENTS WITH AUTOSOMAL
DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
* REGULUS THERAPEUTICS INC- EXPECT TOPLINE DATA FROM OUR
SECOND
COHORT IN Q1 2024, TOPLINE DATA FROM OUR THIRD COHORT IN
MID-2024
Source text for Eikon: ID:nPn1L5n1ba
Further company coverage: RGLS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regulus Therapeutics
See all newsBrief: Novartis Completes Acquisition Of Regulus Therapeutics
Brief: Novartis Announces Expiration Of Hart-Scott-Rodino Waiting Period Of Regulus Therapeutics Tender Offer
Brief: Novartis Announces Commencement Of Tender Offer To Acquire Regulus Therapeutics
Regulus Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Regulus Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview